Attenuation of Arthritis in Rodents by a Novel Orally-available Inhibitor of Sphingosine Kinase

Overview

Journal Inflammopharmacology

Specialty Pharmacology

Date 2010 Oct 12

PMID 20936538

Citations 24

Authors

Leo R Fitzpatrick

Cecelia Green

Elizabeth E Frauenhoffer

Kevin J French

Yan Zhuang

Lynn W Maines

John J Upson

Emmanuel Paul

Henry Donahue

Timothy J Mosher

Charles D Smith

Affiliations

Soon will be listed here.

Abstract

Unlabelled: Pro-inflammatory cytokines like TNF-α activate sphingosine kinase (SK). Therefore, inhibition of SK is a potential molecular target for the treatment of rheumatoid arthritis.

Aims: The primary goal of this study was to assess the efficacy of ABC249640 (a selective SK-2 inhibitor) in two models of rodent arthritis. A secondary goal was to evaluate the pharmacological profile of ABC294640, when given in combination with methotrexate.

Methods: The efficacy of ABC294640 was determined by paw diameter/volume measurements, histological evaluations, and micro-CT analyses.

Results: ABC294640 attenuated both collagen-induced arthritis in mice, as well as adjuvant-induced arthritis in rats. With the adjuvant arthritis model, the prophylactic efficacy profile of ABC294640 was similar to indomethacin. Of note, ABC294640 reduced the bone and cartilage degradation, associated with adjuvant-induced arthritis. Rats treated with a suboptimal dose of MTX (50 μg/kg/day) in combination with ABC249640 (100 mg/kg/day) had better anti-arthritis effects in the adjuvant model, than treatment with either agent alone.

Conclusion: Our results suggest that ABC249640 is an orally available drug candidate with a good pre-clinical efficacy profile for the prevention and/or treatment of RA.

Citing Articles

Phospholipids and Sphingolipids in Osteoarthritis.

Steinmeyer J Biomolecules. 2025; 15(2).

PMID: 40001553 PMC: 11853253. DOI: 10.3390/biom15020250.

Opaganib Downregulates N-Myc Expression and Suppresses In Vitro and In Vivo Growth of Neuroblastoma Cells.

Maines L, Keller S, Smith R, Schrecengost R, Smith C Cancers (Basel). 2024; 16(9).

PMID: 38730731 PMC: 11082966. DOI: 10.3390/cancers16091779.

The Sphingosine Kinase 2 Inhibitor Opaganib Protects Against Acute Kidney Injury in Mice.

Maines L, Green C, Keller S, Fitzpatrick L, Smith C Int J Nephrol Renovasc Dis. 2022; 15:323-334.

PMID: 36420520 PMC: 9677921. DOI: 10.2147/IJNRD.S386396.

Opaganib Protects against Radiation Toxicity: Implications for Homeland Security and Antitumor Radiotherapy.

Maines L, Schrecengost R, Zhuang Y, Keller S, Smith R, Green C Int J Mol Sci. 2022; 23(21).

PMID: 36361977 PMC: 9655569. DOI: 10.3390/ijms232113191.

Recent Progress in the Development of Opaganib for the Treatment of Covid-19.

Smith C, Maines L, Keller S, Ben-Yair V, Fathi R, Plasse T Drug Des Devel Ther. 2022; 16:2199-2211.

PMID: 35855741 PMC: 9288228. DOI: 10.2147/DDDT.S367612.

References

Griffiths R, Pettipher E, Koch K, Farrell C, Breslow R, Conklyn M . Leukotriene B4 plays a critical role in the progression of collagen-induced arthritis. Proc Natl Acad Sci U S A. 1995; 92(2):517-21. PMC: 42772. DOI: 10.1073/pnas.92.2.517. View

Pendley C, Fitzpatrick L, Ewing R, Molino B, Martin G . The gastrin/cholecystokinin-B receptor antagonist L-365,260 reduces basal acid secretion and prevents gastrointestinal damage induced by aspirin, ethanol and cysteamine in the rat. J Pharmacol Exp Ther. 1993; 265(3):1348-54. View

Michaud J, Kohno M, Proia R, Hla T . Normal acute and chronic inflammatory responses in sphingosine kinase 1 knockout mice. FEBS Lett. 2006; 580(19):4607-12. DOI: 10.1016/j.febslet.2006.07.035. View

Anthony D, Haqqi T . Collagen-induced arthritis in mice: an animal model to study the pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol. 1999; 17(2):240-4. View

Hegen M, Sun L, Uozumi N, Kume K, Goad M, Nickerson-Nutter C . Cytosolic phospholipase A2alpha-deficient mice are resistant to collagen-induced arthritis. J Exp Med. 2003; 197(10):1297-302. PMC: 2193788. DOI: 10.1084/jem.20030016. View

MacKinnon A, Buckley A, Chilvers E, Rossi A, Haslett C, Sethi T . Sphingosine kinase: a point of convergence in the action of diverse neutrophil priming agents. J Immunol. 2002; 169(11):6394-400. DOI: 10.4049/jimmunol.169.11.6394. View

Maines L, French K, Wolpert E, Antonetti D, Smith C . Pharmacologic manipulation of sphingosine kinase in retinal endothelial cells: implications for angiogenic ocular diseases. Invest Ophthalmol Vis Sci. 2006; 47(11):5022-31. PMC: 2660407. DOI: 10.1167/iovs.05-1236. View

Kato S, Ogawa Y, Kanatsu K, Okayama M, Watanabe T, Arakawa T . Ulcerogenic influence of selective cyclooxygenase-2 inhibitors in the rat stomach with adjuvant-induced arthritis. J Pharmacol Exp Ther. 2002; 303(2):503-9. DOI: 10.1124/jpet.102.040659. View

Holmdahl R, Bockermann R, Backlund J, Yamada H . The molecular pathogenesis of collagen-induced arthritis in mice--a model for rheumatoid arthritis. Ageing Res Rev. 2002; 1(1):135-47. DOI: 10.1016/s0047-6374(01)00371-2. View

10.

Taha T, Hannun Y, Obeid L . Sphingosine kinase: biochemical and cellular regulation and role in disease. J Biochem Mol Biol. 2006; 39(2):113-31. DOI: 10.5483/bmbrep.2006.39.2.113. View

11.

Maines L, Fitzpatrick L, French K, Zhuang Y, Xia Z, Keller S . Suppression of ulcerative colitis in mice by orally available inhibitors of sphingosine kinase. Dig Dis Sci. 2007; 53(4):997-1012. PMC: 2660406. DOI: 10.1007/s10620-007-0133-6. View

12.

Pettus B, Bielawski J, Porcelli A, Reames D, Johnson K, Morrow J . The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-alpha. FASEB J. 2003; 17(11):1411-21. DOI: 10.1096/fj.02-1038com. View

13.

Oliver S, Brahn E . Combination therapy in rheumatoid arthritis: the animal model perspective. J Rheumatol Suppl. 1996; 44:56-60. View

14.

Hamada T, Arima N, Shindo M, Sugama K, Sasaguri Y . Suppression of adjuvant arthritis of rats by a novel matrix metalloproteinase-inhibitor. Br J Pharmacol. 2001; 131(8):1513-20. PMC: 1572509. DOI: 10.1038/sj.bjp.0703751. View

15.

Goldring M . The role of cytokines as inflammatory mediators in osteoarthritis: lessons from animal models. Connect Tissue Res. 2000; 40(1):1-11. DOI: 10.3109/03008209909005273. View

16.

Wessels J, Huizinga T, Guchelaar H . Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2007; 47(3):249-55. DOI: 10.1093/rheumatology/kem279. View

17.

Luross J, Heaton T, Hirst T, Day M, Williams N . Escherichia coli heat-labile enterotoxin B subunit prevents autoimmune arthritis through induction of regulatory CD4+ T cells. Arthritis Rheum. 2002; 46(6):1671-82. DOI: 10.1002/art.10328. View

18.

French K, Schrecengost R, Lee B, Zhuang Y, Smith S, Eberly J . Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 2003; 63(18):5962-9. View

19.

Feely M, Erickson A, ODell J . Therapeutic options for rheumatoid arthritis. Expert Opin Pharmacother. 2009; 10(13):2095-106. DOI: 10.1517/14656560903071043. View

20.

Brand D . Rodent models of rheumatoid arthritis. Comp Med. 2005; 55(2):114-22. View